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We have used in vitro mutagenesis to examine in detail the roles of two modular protein domains, SH2 and
SH3, in the regulation of the Abl tyrosine kinase. As previously shown, the SH3 domain suppresses an intrinsic
transforming activity of the normally nontransforming c-Abl product in vivo. We show here that this inhibitory
activity is extremely position sensitive, because mutants in which the position of the SH3 domain within the
protein is subtly altered are fully transforming. In contrast to the case in vivo, the SH3 domain has no effect
on the in vitro kinase activity of the purified protein. These results are consistent with a model in which the
SH3 domain binds a cellular inhibitory factor, which in turn must physically interact with other parts of the
kinase. Unlike the SH3 domain, the SH2 domain is required for transforming activity of activated Abl alleles.
We demonstrate that SH2 domains from other proteins (Ras-GTPase-activating protein, Src, p85 phospha-
tidylinositol 3-kinase subunit, and Crk) can complement the absence of the Abl SH2 domain and that mutants
with heterologous SH2 domains induce altered patterns of tyrosine-phosphorylated proteins in vivo. The
positive function of the SH2 domain is relatively position independent, and the effect of multiple SH2 domains
appears to be additive. These results suggest a novel mechanism for regulation of tyrosine kinases in which the
SH2 domain binds to, and thereby enhances the phosphorylation of, a subset of proteins phosphorylated by the
catalytic domain. Our data also suggest that the roles of the SH2 and SH3 domains in the regulation of Abl
are different in several respects from the roles proposed for these domains in the closely related Src family of
tyrosine kinases.
Protein-tyrosine kinases play a central role in the regulation
of cellular growth and differentiation of complex eukaryotes.
The two major classes of tyrosine kinases are the transmem-
brane receptors, which are activated directly by binding of
peptide growth factors and cytokines to their extracellular
domains, and the nonreceptor kinases (for reviews, see refer-
ences 5, 13, and 46). While the normal function of the
receptors as transducers of extracellular signals is evident, the
role of nonreceptor tyrosine kinases is in many cases unknown.
Examples of both classes of kinases have been shown to
function as dominant oncogenes, generally as a result of
overexpression and structural alteration (see reference 14 for a
review).
The Abl nonreceptor tyrosine kinase was originally isolated
as the transforming gene of Abelson murine leukemia virus
(12) and was subsequently shown to be involved in human
leukemias by virtue of a chromosomal translocation resulting
in the expression of a fusion protein containing N-terminal
sequences from a second locus, bcr (28, 48). Overexpression of
c-Abl does not result in efficient cell transformation or ele-
vated tyrosine phosphorylation in vivo (10, 15), whereas struc-
turally altered forms are able to efficiently induce transforma-
tion and elevated phosphotyrosine in a variety of cell types,
suggesting that the activity of the normal kinase is tightly
regulated. As in the Src family of tyrosine kinases, N terminal
to the catalytic domain of Abl are two small modular domains
termed the Src homology 2 and 3 (SH2 and SH3) domains.
Previous work in a number of laboratories has suggested that
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the SH2 and SH3 domains of nonreceptor tyrosine kinases are
involved in regulation of kinase activity in vivo.
SH2 and SH3 domains are found in a wide variety of
proteins and are thought to function by mediating controlled
protein-protein interactions (reviewed in references 24 and
34). SH3 domains are implicated in the repression of activity of
Abl and the Src family kinases, because deletion or mutation of
this domain generally activates the transforming activity of the
proto-oncogenes (10, 15, 17, 39). Several SH3 domain-binding
proteins have now been isolated, and a proline-rich binding
motif for the Abl SH3 domain has been identified (4, 41). SH2
domains have been shown to bind specifically and with high
affinity to tyrosine-phosphorylated proteins (la, 20, 23, 25, 30)
and are thought to mediate the association of signaling pro-
teins in response to tyrosine phosphorylation. We have previ-
ously shown that activated Abl proteins with mutated SH2
domains that are no longer able to efficiently bind tyrosine-
phosphorylated proteins are impaired in their ability to trans-
form (26).
We have devised a mutagenesis scheme that facilitates the
deletion, reiteration, swapping, and movement within the
protein of various modular domains of the Abl tyrosine kinase.
These mutants have been used to examine in detail the roles of
the SH2 and SH3 domains in the regulation of Abl activity. As
expected from previous results, we find that the SH2 and SH3
domains play very different roles: the SH3 domain appears to
suppress the intrinsic transforming ability of Abl, while the
SH2 is absolutely required for expression of the transforming
activity of activated Abl genes. We extend these observations
to show that in cells, the inhibitory activity of the SH3 domain
is extremely sensitive to its position in the Abl molecule, but its
presence or absence has no effect on the in vitro kinase activity
of the purified protein, suggesting that the SH3 domain
regulates kinase activity in vivo by a complex mechanism. We
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also find that the SH2 domain, not the catalytic domain, is
largely responsible for determining the spectrum of proteins
phosphorylated in vivo. We propose that the SH2 domain is
required for transforming activity because it modulates the
output of a relatively nonspecific catalytic domain by directly
binding to, and enhancing the phosphorylation of, a subset of
proteins phosphorylated by the catalytic domain.
MATERUILS AND METHODS
Construction of Abi Mutants. All Abl genes were con-
structed from modular fragments generated by PCR using
wild-type murine type IV c-Abl cDNA (pPLcIV) (2, 15) and
primers encoding unique restriction sites on their 5' ends. Pfu
DNA polymerase (Stratagene) was used as recommended by
the manufacturer except that elongation times were occasion-
ally extended to 5 min to generate longer fragments. PCR
primers had 24 to 30 nucleotides (nt) of identity with template,
6 or 8 nt encoding restriction sites, and five or six G or C
residues 5' to clamp the ends of the fragment to facilitate
restriction digestion. All PCR fragments were sequenced to
approximately 200 nt from each end; no mutations were
observed in any clone except in regions of primer binding. Only
clones of the expected sequence were used for further studies.
The prototype modular c-Abl gene (termed construct F)
consisted of three PCR fragments (all nucleotide numbers are
relative to the A of the initiation codon of murine type IV
c-Abl): N-terminal fragment A (Notl, nt -9 to 252, SacII),
SH3-plus-SH2 fragment F (SacII, nt 256 to 723, BamHI), and
catalytic domain-plus-C-terminus fragment B (BamHI, nt 730
to 3465, NotI). Deletions of SH2 or SH3 were generated by
replacing fragment F with fragment E (SacII, nt 256 to 417,
BamHI) or fragment G (SaclI, nt 427 to- 723, BamHI), to
generate constructs E and G, respectively; deletion of both was
effected by replacing fragment F with a short synthetic adaptor
(top strand, 5' TCGCGAACA; bottom strand, 5' GATCTGT
TCGCGAGC) to generate construct 9. For constructs with
SH2 and/or SH3 domains C terminal to the catalytic domain,
two other fragments were generated using construct 9 DNA as
the template: N-terminal and catalytic domain fragment C
(Notl, nt -9 to 1620, SacIl) and C-terminal fragment D
(BamHI, nt 1621 to 3465, Notl).
All constructs were initially manipulated while cloned into
a modified vector derived from pBS-SK(- ) (Stratagene),
termed pBSA, in which the vector SacII and BamHI sites had
been destroyed. For virus production, NotI Abl fragments were
cloned into pGDN, a derivative of the retroviral vector pGD
(7) in which the XhoI cloning site had been converted to a
unique NotI site. All constructs were derived from the same
cloned PCR fragments A, B, C, D, E, F, and G so that there
could be no clone-to clone variation due to Pfu polymerase
errors. Further details of the construction of all mutants
described here can be provided on request.
For mutants in which portions of Abl are swapped with
heterologous SH2 or catalytic domains, fragments were gen-
erated by PCR as described above with appropriate restriction
sites. All SH2 domains contained 5' SacIl and 3' BamHI sites
and consisted of the following amino acids: murine N-terminal
GTPase-activating protein (GAP) SH2 domain, corresponding
to amino acids (aa) 178 to 274 of human GAP (52); murine Src
SH2 domain, aa 153 to 255 of neuronal form (21); murine p85
phosphatidylinositol (PI) 3-kinase subunit C-terminal SH2
domain, aa 618 to 720 (8); and chicken c-Crk SH2 domain, aa
7 to 121 (40). The Src catalytic domain consisted of aa 249 to
524 of chicken c-Src (corresponding to aa 257 to 532 of murine
neuronal form [21]), with 5' BamHI and 3' BglII sites. This was
ligated to the NotI-BamHI N-terminal-plus-SH2 domain frag-
ments containing various SH2 domains and the BamHI-NotI
C-terminal D fragment to generate the GSC series of mutants.
Generation of virus and assay of biological activity. Infec-
tious virus expressing various Abl genes was produced by
transient transfection of 293 cells. Generally 2 to 5 ,ug of
pGDN-derived plasmid and 2 to 5 ,ug of pZAP, which encodes
intact Moloney murine leukemia virus (15), were introduced
by calcium phosphate coprecipitation into 4 x 106 293 cells in
a 10-cm-diameter plate. In some experiments, chloroquine was
added to 25 ,iM just prior to transfection. The medium was
changed after approximately 8 h, and virus stocks were col-
lected 2 days later. 293 cells were cultured in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf
serum and antibiotics.
Focus assays and G418-resistant colony assays were deter-
mined on NIH 3T3 cells. Only early-passage cells of a subclone
chosen for flat morphology were used to assay transformation.
3T3 cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% donor calf serum plus anti-
biotics. Six-centimeter-diameter dishes seeded with approxi-
mately 105 cells were infected with 1 ml of diluted virus and 1
ml of medium supplemented with 16 ,ug of Polybrene per ml.
Virus was removed after 8 h and replaced with fresh medium.
To select G418-resistant colonies, medium was changed to
medium containing 1 mg of G418 per ml the next day. All
plates were fed at 3-day intervals thereafter. Morphologically
altered foci were scored 7 to 10 days postinfection, and
G418-resistant colonies were scored 10 to 14 days postinfec-
tion.
Transient infections and protein characterization. For anal-
ysis of tyrosine-phosphorylated proteins induced by Abl SH2
domain mutants, 2.5 x 105 3T3 cells were infected in 10-cm-
diameter dishes with 4 ml of undiluted virus stocks (multiplicity
of infection of -1). Two days postinfection, cells were lysed in
0.5 ml of Triton extraction buffer (TXB; 10 mM Tris [pH 7.4],
150 mM NaCl, 5 mM Na2EDTA, 10% glycerol, 1% Triton
X-100, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride,
20 jig of aprotinin per ml) on ice for 30 min and centrifuged for
10 min in a microcentrifuge to clear, and protein concentra-
tions were assayed by the Bradford method (Bio-Rad). For
immunoblotting, equal amounts of cell protein were separated
on sodium dodecyl sulfate (SDS)-polyacrylamide gels and
transferred to nitrocellulose in 10 mM CAPS (pH 11)-20%
methanol for 2 h at 500 mA. Filters were blocked in TBST (10
mM Tris [pH 8.0], 0.9% NaCl, 0.05% Tween 20) with 1%
ovalbumin and 0.02% NaN3 for several hours at 4°C and then
incubated overnight at 4°C in blocking buffer containing either
a combination of monoclonal antibodies 4G10 (Upstate Bio-
chemical, Inc.) and PY20 (11) (for antiphosphotyrosine blot-
ting) or affinity-purified rabbit polyclonal antibody directed
against the Abl type IV-specific N-terminal sequences. After
washing with TBST, filters were incubated with alkaline phos-
phatase-conjugated donkey anti-mouse immunoglobulin (for
antiphosphotyrosine blotting) or either alkaline phosphatase-
conjugated protein A or alkaline phosphatase-conjugated don-
key anti-rabbit immunoglobulin, washed again, and developed
with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-
phosphate toluidinium.
For anti-Abl immunoprecipitations, equal amounts of cell
protein were incubated on ice with crude Abl-specific pEX-4
serum (19). Immunoprecipitates were collected on protein
A-Sepharose beads, washed three times with lysis buffer,
resuspended in sample buffer, boiled, and separated on SDS-
polyacrylamide gels. For antiphosphotyrosine immunoprecipi-
tates, Affi-Gel-Hz beads (Bio-Rad) were covalently coupled
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to phosphotyrosine-specific monoclonal antibody PY20 for a
final concentration of 2.5 mg of immunoglobulin per ml of
beads, following the manufacturer's recommendations. Equal
amounts of cell protein were incubated on ice with PY20 beads
and then washed, electrophoresed, and immunoblotted as
described above.
Production and characterization of GST-Abl fusion pro-
teins. The glutathione S-transferase (GST) fragment from
pGEX-2T (49) was modified by PCR so that the initiation
codon was preceded by a eukaryotic Kozak consensus ribo-
some binding site and a 5' BglII site. The BglII-BamHI 0.7-kb
fragment so generated was cloned into the unique BamHI site
of baculovirus vector pVL1393 (Invitrogen, Inc.) to generate
plasmid pVLGS. The Abl genes of construct E, F, and G
described above were inserted into pVLGS. To do this, an
alternative N-terminal fragment A was synthesized by PCR,
consisting of BamHI, nt 4 to 252, SacII. This fragment was
ligated along with the SaclI-NotI fragments from pBSA-E, -F,
or -G into pVLGS cut with BamHI and NotI.
Recombinant baculovirus was generated by transfection of
Sf9 cells with pVLGS derivatives along with wild-type Auto-
grapha califomica nuclear polyhedrosis virus DNA, using stan-
dard protocols. In each case, several independent clones were
plaque purified and characterized. For protein production,
Sf21 cells (Invitrogen) were infected with high-titer virus in
1-liter roller bottles (approximately 20 ml of virus per 108
cells). After 90 min, 180 ml of Grace's medium (supplemented
with 10% fetal bovine serum, 2% [vol/vol] yeastolate, and
lactalbumin hydrolysate [GIBCO] plus antibiotics) was added,
and bottles were incubated at 26°C for a further 2 days. Cells
were harvested, washed in cold phosphate-buffered saline, and
lysed in TXB with 1 mM dithiothreitol on ice for 30 min, and
lysates were cleared by centrifugation at 12,000 x g for 15 min.
GST fusion proteins were purified by incubating lysates with
glutathione-agarose beads (Molecular Probes, Inc.) at 4°C for
90 min, washing extensively in TNGT buffer (10 mM Tris [pH
8.0], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM
dithiothreitol), and eluting with TNGT plus 20 mM reduced
glutathione and 100 mM Tris (pH 8.8). For thrombin cleavage,
washed glutathione-agarose beads bound to GST-Abl fusion
proteins were incubated with an empirically determined
amount of human thrombin (Calbiochem) in TNGT supple-
mented with 2.5 mM CaCl2, and the eluted cleaved Abl
proteins were separated from beads by pouring into a dispos-
able column. Na2EDTA was added to 2.5 mM, and phenyl-
methylsulfonyl fluoride was added to 1 mM to inactivate
thrombin. Purified proteins were stored at - 70°C.
For in vitro kinase assays, purified proteins were incubated
in 50 mM N-2-hydroxyethy piperazine-N'-2-ethanesulfonic
acid (HEPES; pH 7.5)-5 mM MgCl2-0.5 mg of poly(Glu-Tyr)
(4:1; Sigma P-0275) per ml-50 ,ug of acetylated bovine serum
albumin (BSA) per ml-1 mM cold ATP-10 ,uCi of [-y-32P]ATP
in 20 ,ul (total volume) at 4°C for 20 min. Reactions were
stopped with 5 [lI of 5 x Laemmli sample buffer, boiled, and
run on SDS-polyacrylamide gels. Gels were stained with Coo-
massie blue, fixed in 10% acetic acid-20% methanol, dried,
and exposed for autoradiography. Quantitative assays using
angiotensin as a substrate were performed essentially as de-
scribed previously (9). Reaction mixtures contained 50 mM
HEPES (pH 7.5), 10 mM MgCl2, 100 puM [-y-32P]ATP (-1,000
cpm/pmol), and 1 mg of [Val5] angiotensin II (Sigma A-2900)
per ml. Reactions were performed at 30°C, and 25-iil aliquots
were stopped at various time points with 35 p.l of 10%
trichloroacetic acid and incubated on ice. Aliquots were briefly
centrifuged, and 30 p[L of the supernatant was spotted on a
4-cm2 piece of phosphocellulose paper (Whatman P81). Filters
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FIG. 1. Effects ofSH3 andSH2 domains on transforming activities
of c-Abl-derived mutants. Mutants are depicted diagrammatically.
Black boxes, SH3 domain; white boxes, SH2 domain; hatched boxes,
catalytic domain. Arrowheads indicated the position of unique restric-
tion sites inserted by PCR. The white triangle indicates the position of
short synthetic adaptor sequence. K171 denotes a mutant SH2 domain
with an arginine-to-lysine mutation at position 171 that drastically
reduces binding to phosphotyrosine. Transforming activity value given
is the normalized average of morphologically transformed foci per 104
G418-resistant colonies for each mutant (see Table 1 and text for
details). ffu, focus-forming units.
were washed three times with ice-cold 0.5% phosphoric acid,
washed once with acetone, and dried, and Cerenkov counts
were determined. Data points shown are the mean of triplicate
samples.
RESULTS
To analyze the roles of the SH2 and SH3 domains in Abl, we
constructed a modularized Abl gene by inserting unique
restriction sites flanking the SH3 and SH2 domains, using PCR
(Fig. 1). This cassette system allowed individual SH2 or SH3
domains or the block of SH3 plus SH2 domains to be easily
manipulated. For some constructs, another unique site was
inserted C terminal to the catalytic domain, allowing insertion
of sequences or swapping of catalytic domains. The location of
all linkers was chosen to be in predicted loop regions between
modular units of protein structure so that disruption of sec-
ondary and tertiary structure of the resulting proteins would be
minimized. Furthermore, the spacing between elements of
structure was conserved in the mutants. All of the constructs in
this study encode the myristoylated type IV N terminus of Abl,
because previous studies have shown that it is difficult to
overexpress proteins encoding the nonmyristoylated type I N
terminus (10, 15a).
All mutant Abl genes were inserted into a simple retroviral
vector derived from pGD (7). This vector contains all se-
quences required in cis for expression and packaging of the
genome and also encodes the neomycin resistance gene,
allowing selection of infected cells with G418. When cotrans-
fected with pZAP, which encodes a replication-competent
Moloney murine leukemia virus helper, infectious particles
encoding the mutant Abl genes are produced.
A transient transfection system was used to produce virus for
these studies (36). 293 cells, a human kidney-derived cell line,
were transfected with helper and pGD-derived plasmids, and
virus was harvested 2 days posttransfection. This protocol
minimizes mutation due to error-prone reverse transcription,
t
t
t
t
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TABLE 1. Quantification of transformed foci and G418-resistant colonies
Mutant
Raw data' Foci/104 Normalized' Avg' ne
Foci/ml CFU/ml CFUh
GDN <10 7.2 x 105 <11 <1 <1 10
E <10 6.8 x 105 <1 <1 <1 2
F 580 4.0 x 104 145 85 140 3
G 8.9 x 104 5.2 x 104 1.7 x 104 104 104 10
9 <10 7.4 x 105 <1 <1 <1 2
DE NDf ND <4 2
DF ND ND <10 2
DG 15 6.5 x 104 <3 <2 <2.5 2
D9 ND ND <2 2
K171 320 2.0 x 105 16 9.4 9.4 2
23 2.7 x 104 3.6x 104 7.5x 103 4.4 x 103 5.2 x 103 2
323 1.1 x 104 2.3 x 104 4.8 x 103 2.8 x 103 2.5 x 103 3
FN 3.5 x 104 2.2x 104 1.6x 104 9.4 x 103 6.1x 103 5
GG 1.5 x 103 7.2 x 104 210 120 120 4
GS 5.2 x 103 8.5 x 104 620 360 510 3
GP 6.2 x 104 5.0x 104 1.2 x 104 7.1 x103 3.3 x 103 3
GC 1.4 x 105 1.4x 104 105 5.9 x 104 2.2 x 104 4
GSC 2.4 x 103 4.6 x 104 520 310 460 3
GSC-G 2.6 x 103 4.7 x 104 550 320 340 2
GSC-S 1.1 x 104 5.5 x 104 2.0 x 103 1.2 x 103 1.2 x 103 2
GSC-P 2.7 x 104 2.8 x 104 9.6 x 103 5.6 x 103 4.9 x 103 2
GSC-C 9.2 x 103 1.3 x 103 7.1 x 104 4.2 x 104 1.9 X 104 3
GAG ND ND 9.4 x 103 2
GGA ND ND 1.2 x 104 2
2N3K2 2.0 x 104 2.0 x 104 104 5.9 X 103 5.8 x 103 2
K2N32 1.9 x 104 2.8 x 104 6.8 x 103 4.0 x 103 4.2 x 103 2
a Data from a single transfection and subsequent assay of morphologically transformed focus titer and G418 resistance colony titer.
b Transformed focus titer normalized to G418 resistance colony titer.
Values from previous column normalized to give the mutant G a value of 104 foci/104 CFU (i.e., in this case dividing all values by 1.7).dMean normalized titer (averaged over the number of independent experiments given in the next column).
Number of independent transfections used to generate average normalized titer (previous column).
f ND, not done in this experiment.
because at most two rounds of replication are undergone
before the mutant genome is scored for biological activity.
Transforming activity was assessed by infection of NIH 3T3
cells with dilutions of the 293 cell-derived virus and scoring
parallel sets of dishes for morphologically transformed foci and
G418-resistant colonies.
The raw numbers of transformed foci and G418-resistant
colonies varied considerably from experiment to experiment,
so data were normalized in two ways (Table 1). First, all
transformation scores were normalized to virus titer by divid-
ing transformed foci by G418-resistant colonies and expressed
as transformed foci per 104 G418-resistant colonies. A second
normalization was required so that data from separate trans-
fections could be combined and averaged. This involved mul-
tiplying all scores within a given experiment by a normalization
constant such that a fully transforming benchmark mutant
(GDN-G) had a score of 104 foci per 104 G418-resistant
colonies (in practice, the normalization constant had values of
between 0.5 and 2). All transformation data reported in this
paper were derived from at least two independent transfec-
tions. Raw data from one representative experiment is shown
in Table 1 for reference.
For all mutants, transfected 293 cells used for production of
virus were also analyzed by Western blotting (immunoblotting)
with Abl-specific antisera. This analysis confirmed that the
mutant proteins were of the expected molecular weight and
were produced in reasonable quantities (data not shown). In
vitro kinase assays were also performed on immunoprecipi-
tates from the 293 cell lysates to ensure that the mutant
proteins were active as protein-tyrosine kinases (data not
shown).
Effect of SH2 and SH3 domain deletion. The first series of
mutants was constructed to test whether our mutagenic ap-
proach was viable and to confirm the presumed inhibitory role
of the SH3 domain and positive role of the SH2 domain in
transformation by Abl (Fig. 1). When the linker-modified
c-Abl construct (termed GDN-F) was assayed for transforming
activity, only very low activity was observed (less than 150 foci
per 104 G418-resistant colonies). We believe that this weak
transforming activity was detected in our experiments, unlike
earlier studies (10, 15, 32), because our expression strategy did
not involve long-term selection of cells expressing c-Abl, which
is strongly cytostatic (15, 1Sa, 42) and we assayed morpholog-
ical alteration and not soft-agar colony growth. It is also
possible that the insertion of two restriction sites by PCR had
a slight activating effect. This c-Abl background was very small,
however, relative to the transforming activity of a mutant in
which the SH3 domain was deleted (GDN-G), which was
approximately 100-fold higher. In a number of separate exper-
iments, focus-forming titers with this virus were approximately
equal to G418 resistance titers suggesting that virtually every
infected cell produced a morphologically transformed focus.
These foci were in general larger than the few foci seen with
the undeleted c-Abl-expressing construct.
When the SH2 domain was deleted, either in the presence or
in the absence of the SH3 domain (GDN-E and -9, respective-
ly), transforming activity was undetectable (Fig. 1). Further-
more, when the SH2 domain of a mutant lacking the SH3
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FIG. 2. Effects of altering positions ofSH3 and SH2 domains on
transforming activities of Abl mutants. Structures and transforming
activities are depicted as in Fig. 1. (A) Mutants with SH2 domains N
terminal to the catalytic domain. (B) Mutants with SH2 and SH3
domains deleted from their normal N-terminal positions and intro-
duced C terminal to the catalytic domain. ffu, focus-forming units.
contained an arginine-to-lysine mutation at position 171
(R171K), which has been shown to be essential for binding to
phosphotyrosine (26), transforming activity was drastically
reduced relative to the same construct with an unmutated SH2
domain. These results are consistent with previously published
results showing that deletion of the SH3 domain leads to
activation of c-Abl and that a functional SH2 domain is
required for transforming activity. Therefore, the insertion of
linkers by PCR did not significantly alter the biological activity
of Abl or mutants derived from it.
Position dependence of SH2 and SH3 domain function. The
next series of mutants was constructed to test whether the
negative function of the SH3 domain and the positive function
of the SH2 domain were dependent on their positions within
the Abl protein. Mutants were constructed in which the
positions of the SH2 and SH3 domains were changed relative
to each other and to the N terminus or catalytic domain. These
mutants contained at least one functional SH2 and SH3
domain, and some contained an additional SH2 domain with
the R171K mutation to render it nonfunctional. All of these
mutants had transforming activities nearly as great as that of
the SH3 domain-deleted positive control (Fig. 2A), demon-
strating that the context of the SH3 domain is extremely
important to its ability to inhibit transforming activity of Abl.
It is clear from these mutants that the relationship with more
than one part of the protein is important, since in at least one
of the mutants, the position of the SH3 domain is unchanged
relative to either the N terminus, SH2 or catalytic domain, and
C terminus. In mutant 23, the positions of the SH2 and SH3
domains are swapped, and the SH3 domain is in an altered
position relative to the N terminus, SH2 domain, and catalytic
domain. In mutant 323, a second SH3 domain is inserted
between the SH2 and catalytic domains; the position of the
N-terminal SH3 domain is altered only relative to the catalytic
domain. In mutant FN, three amino acids were inserted
between the SH3 and SH2 domains, subtly altering the posi-
tion of the SH3 domain relative to the catalytic and SH2
domains. In mutant 2N3K2, the SH3 domain is in an altered
position relative to the N terminus and the functional SH2
domain, and in mutant K2N32, a nonfunctional SH2 domain is
inserted upstream of the SH3 domain, altering its position only
relative to the N terminus.
Another implication of the results shown in Fig. 2A is that
unlike the SH3 domain, the SH2 domain can function in
different positions within the Abl protein. In mutant GDN-
2N3K2, the functional SH2 domain is approximately 150 aa N
terminal to its normal position relative to the catalytic domain,
yet transforming activity is essentially equivalent to that of the
positive SH3 domain-deleted control. To test whether the SH2
or SH3 domain could function in a radically different context,
a series of mutants was constructed with the SH3 and SH2
domains deleted from their normal positions N terminal to the
catalytic domain and inserted alone or in combination in a
novel position C terminal to the catalytic domain (Fig. 2B).
None of these constructs had significant transforming activity,
although they produced proteins that were kinase active and
present in amounts comparable to those shown in Fig. 2A
(data not shown). This finding demonstrates that while there
can be considerable flexibility in the position of the SH2
domain, it is not entirely position independent since it cannot
effectively perform its positive role when C terminal to the
catalytic domain.
Complementation of loss of the SH2 domain by heterolo-
gous SH2 domains. SH2 domains all have the ability to bind to
tyrosine-phosphorylated proteins, but different SH2 domains
bind to different specific binding sites (50). We were therefore
interested in whether Abl transformation was dependent on
the presence of the Abl SH2 domain, or whether SH2 domains
from other proteins, with different binding specificities, would
restore transforming ability in Abl mutants lacking the Abl
SH2 domain. We constructed a series of mutants in which the
SH3 domain was deleted to activate the transforming activity
of c-Abl, and the Abl SH2 domain was replaced by the SH2
domain of Src or Crk, the N-terminal SH2 domain of GAP, or
the C-terminal SH2 domain of the p85 PI 3-kinase subunit
(Fig. 3A). When assayed, all of the mutants with heterologous
SH2 domains had detectable transforming activity, whereas
transformation was undetectable in the absence of any SH2
domain. Activities ranged from 100-fold less active (for the
GAP SH2 domain) to at least as active (for the Crk SH2
domain) as the Abl SH2 domain-containing positive control(Fig. 3A). This finding demonstrates that transforming activity
is not strictly dependent on the Abl SH2 domain, and that SH2
domains with very different binding specificities could function
to promote transforming activity. The very low activity of the
construct with the mutant Abl SH2 domain that is unable to
bind to phosphotyrosine (GDN-K171 in Fig. 1) demonstrates
that this requirement is not merely structural but requires the
ability to bind to phosphotyrosine.
When viruses encoding the SH2 domain swap mutants
described above were used to infect 3T3 cells and tyrosine-
phosphorylated proteins were analyzed by immunoblotting,
the pattern of tyrosine phosphorylation differed in the mutants(Fig. 4A). The pattern of phosphoproteins seemed to correlate
with the proteins for which the specific SH2 domain had high
affinity. For example, we have previously shown that the
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FIG. 3. Effects of heterologous SH2 and catalytic domains on
transforming activities of Abl mutants. Structures and transforming
activities are depicted as in Fig. 1. The origin of the SH2 domain is
indicated within the white boxes. GAP, N-terminal SH2 domain of
Ras-GAP; PIK, C-terminal SH2 of p85 subunit of PI 3-kinase. (A)
Mutants with the Abl catalytic domain. (B) Mutants in which the Abl
catalytic domain is replaced with that of Src. ffu, focus-forming units.
N-terminal GAP SH2 domain has a very high affinity for a
protein of approximately 68 kDa (26), and a tyrosine-phos-
phorylated protein of this molecular mass is most prominent in
cells infected by the GAP SH2 domain-containing mutant.
Similarly, the Crk SH2 domain has high affinity for proteins in
the 135- to 155-kDa range (3, 22, 24a), and tyrosine-phosphor-
A B
ylated proteins of this molecular mass are prominent in cells
infected with the Crk SH2 domain-containing mutant. Surpris-
ingly, there was no apparent correlation between overall
phosphotyrosine levels and transforming efficiency.
We next examined whether any of the tyrosine-phosphory-
lated proteins were physically associated with the Abl proteins.
We immunoprecipitated Abl from infected cell lysates, sepa-
rated the immunoprecipitated proteins on gels, and immuno-
blotted them with a phosphotyrosine-specific antibody (Fig.
4C). In each lane, several tyrosine-phosphorylated proteins in
addition to Abl itself were observed, suggesting that they were
physically associated with the Abl product. Furthermore, the
pattern of coprecipitating proteins varied with the SH2 do-
main, accentuating the differences seen in whole lysates and
suggesting that these tyrosine-phosphorylated proteins might
be bound to Abl by SH2-phosphotyrosine interactions and that
this might be the cause of the difference in the overall pattern
of tyrosine phosphorylation.
Effect of replacing the Abl catalytic domain. Since the
experiments described above suggested that the pattern of
phosphoproteins observed when activated Abl is overex-
pressed depends on the SH2 domain, we examined the role of
the catalytic domain in determining this pattern. We generated
a series of mutants with various SH2 domains, similar to those
shown in Fig. 3A but with the Abl catalytic domain replaced
with that of p60csrc. As shown in Fig. 3B, all of these mutants
had detectable transforming activity. In fact, the hierarchy of
transforming activities was very similar to that seen with the
Abl catalytic domain: the Crk SH2 domain was the most
efficient, followed by that of PI 3-kinase, with the GAP SH2
being the least efficient. The two cases where the correlation
broke down were when the Abl and Src SH2 domains were
involved; in each case, the catalytic domain was most efficient
when paired with its corresponding SH2 domain. It is remark-
able that mutant GSC-C contained pieces of three proteins (N
and C termini of Abl, SH2 domain of Crk, and catalytic
domain of Src) and was as transforming as the most highly
activated Abl variants, demonstrating the truly modular nature
of these proteins.
The pattern of tyrosine-phosphorylated proteins was also
examined in these mutants (Fig. 5A). Again, as in the case with
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FIG. 4. Characterization of tyrosine-phosphorylated proteins in cells expressing SH2 domain swap mutants. 3T3 cells were infected with
high-titer virus stocks expressing mutant Abl genes depicted in Fig. 3A, and lysates were prepared 2 days later. Lanes contain lysates from cells
infected with virus as marked. Numbers on the left indicate apparent molecular mass markers in kilodaltons. Arrows indicate approximate positions
of mutant Abl proteins. (A) Antiphosphosphotyrosine immunoblot of whole cell lysates. (B) Immunoblot of same lysates with Abl-specific
antiserum. (C) Antiphosphotyrosine immunoblot of lysates first immunoprecipitated with Abl-specific serum, showing tyrosine-phosphorylated
proteins that coprecipitate with Abl protein.
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FIG. 5. Tyrosine-phosphorylated proteins in cells expressing mutants with heterologous SH2 and catalytic domains. 3T3 cells were infected with
virus-expressing mutants depicted in Fig. 3, and lysates were prepared 2 days after infection. Lanes are as marked; molecular mass markers are
as depicted as in Fig. 4. Approximate positions of Abl proteins are indicated by arrows. In panel D, dots indicate the positions of
tyrosine-phosphorylated proteins characteristic of mutants containing the GAP, PI 3-kinase, or Crk SH2 domain (approximate molecular masses
of 68, 180, and 135 to 155 kDa, respectively). (A) Antiphosphotyrosine immunoblot of whole cell lysates. (B) Antiphosphotyrosine immunoblots
of lysates first partially purified by binding to beads covalently coupled to antiphosphotyrosine-specific antibody. (C) Immunoblot of whole cell
lysates probed with Abl-specific antiserum. (D) Antiphosphotyrosine immunoblot of lysates first immunoprecipitated with Abl-specific antiserum,
showing coprecipitating tyrosine-phosphorylated proteins.
the Abl SH2 domain, the pattern of tyrosine-phosphorylated
proteins varied with the SH2 domain. This is more easily seen
when the tyrosine-phosphorylated proteins were first immuno-
precipitated with antiphosphotyrosine antibody beads (Fig.
5B) or when proteins that coprecipitated with Abl were
analyzed (Fig. 5D) because it has proven difficult to get
high-level expression of the mutants with the Src catalytic
domain in transient infections (Fig. 5C). These results suggest
that the SH2 domain plays at least as important a role in
determining the pattern of tyrosine-phosphorylated proteins
seen in cells infected with these Abl mutants as the catalytic
domain does.
Role of multiple SH2 domains. We have shown that the
transforming potency and ultimate substrate specificity of Abl
mutants is highly dependent on the SH2 domain. We were
further interested in whether the effect of multiple SH2
domains would be additive, or whether the properties of one
SH2 domain would be dominant in a construct that encoded
multiple SH2 domains. For this purpose, we constructed two
mutants that contained both the Abl and N-terminal GAP SH2
domains, in the order Abl-GAP or GAP-Abl (Fig. 6). We used
these two SH2 domains because they had the greatest disparity
in both transforming activity (100-fold) and the pattern of
tyrosine-phosphorylated proteins observed (where the GAP
SH2 induces the prominent 68-kDa phosphoprotein). Both of
these mutants had transforming activities essentially indistin-
guishable from that of the positive control encoding the Abl
SH2 domain, suggesting that both the proximal and distal SH2
domains were able to function to promote transformation (Fig.
6). Furthermore, when the pattern of tyrosine-phosphorylated
Transforming
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FIG. 6. Mutants containing multiple SH2 domains. Structures and
transforming activities of mutants are depicted as in Fig. 1. The origin
of each SH2 domain (Abl or N-terminal Ras-GAP SH2 domain) is
indicated in a white box. ffu, focus-forming units.
... .. ...... ~~~~~~"o
.. W: .B.'
t
VOL. 14, 1994
2890 MAYER AND BALTIMORE
A
MOL. CELL. BIOL.
B A B
0) 0~0000)
216
-1
105-
70-
43-
h-
0
D 4
>aG 0(
>I
FIG. 7. Tyrosine-phosphorylated proteins in mutants containing
multiple SH2 domains. 3T3 cells were infected with virus-expressing
mutants depicted in Fig. 6, and lysates were prepared 2 days postin-
fection. Lanes are as marked; markers are as in Fig. 4. The arrow
indicates the approximate position of Abl proteins. (A) Antiphospho-
tyrosine immunoblot of whole cell lysates. (B) Antiphosphotyrosine
immunoblot of lysates first immunoprecipitated with Abl-specific
antiserum, showing coprecipitating tyrosine-phosphorylated proteins.
proteins was analyzed, the two mutants induced similar pat-
terns that seemed to be the sum of the patterns observed when
each SH2 domain was present alone (Fig. 7A). This was even
clearer when the tyrosine-phosphorylated proteins that copre-
cipitated with Abl were visualized (Fig. 7B). These results
demonstrate that the SH2 domains function independently and
that proximity to the catalytic domain does not appear to affect
their activities significantly. The SH2 domains function addi-
tively in that properties of each (efficient transformation by the
Abl SH2, phosphorylation of the 68-kDa protein by that of
GAP) are conferred on proteins containing both of them.
Effect of SH2 and SH3 domains on purified protein. It is
clear from the data presented above that the SH2 and SH3
domains have a profound effect on in vivo activity of the Abl
protein. To examine the effect of deletion of these domains on
the in vitro activity of purified protein, we have constructed
GST fusion proteins encoding the Abl inserts of GDN-F, -G,
and -E (intact, SH3 domain-deleted, and SH2 domain-deleted
c-Abl, respectively; Fig. 1). In each case, GST was fused
directly upstream of the position 2 glycine of Abl, so that
cleavage with thrombin generated the natural Abl N terminus
except for the lack of the N-terminal myristoyl moiety. The
fusion proteins were expressed either in insect cells by using
baculovirus vectors or in human 293 cells by using an expres-
sion vector driven by the elongation factor lcx promoter (29).
In both cases, large quantities of protein were easily purified
on glutathione-agarose beads and either eluted with glutathi-
one or cleaved with thrombin.
When the in vitro kinase activities of the three different Abl
proteins were compared, there was no apparent difference
(Fig. 8). This was true whether or not the proteins were cleaved
from GST (Fig. 8A) or whether proteins were synthesized in
insect cells or human cells (not shown). Kinase activity was
measured using Abl itself or poly(Glu-Tyr) random copolymer
as the substrate and visualized on gels (Fig. 8A) or by using
angiotensin II or [Val'] angiotensin II in a quantitative filter
paper assay (Fig. 8C); in all cases, the three proteins had
essentially identical kinase activities per microgram of Abl
protein (differences of less than a factor of 2). With use of
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FIG. 8. Effects of SH2 and SH3 domains on in vitro kinase activity
of purified GST-Abl fusion proteins. GST-Abl fusion proteins encod-
ing the Abl genes of mutants E, F, and G (see Fig. 1) were produced
in insect cells and purified on glutathione-agarose. Proteins were either
eluted or cleaved with thrombin to remove GST, as marked. (A and B)
Approximately equal amounts of the six purified protein samples were
incubated with [,y-32P]ATP and poly(Glu-Tyr) random copolymer to
assess kinase activity. Reactions were run on SDS-polyacrylamide gels,
stained with Coomassie blue, fixed, dried, and autoradiographed (A)
or photographed directly (B). Phosphorylated substrate poly(Glu-Tyr)
appears as a smear in panel A. The band at -85 kDa in panel B
(arrow) is acetylated BSA carrier protein. The approximate position of
the full-length Abl proteins is indicated on panel B. Molecular mass
markers are as in Fig. 4. (C) Rates of reaction of purified GST fusion
proteins were assessed in vitro, using [Val5] angiotensin II as the
substrate. Results were normalized for protein content.
[Val5] angiotensin II at 1 mM, initial reaction rates ranged
from approximately 7 to 11 pmol of phosphate per min per
pmol of Abl protein (Fig. 8C and data not shown). These
results suggest that the SH3 and SH2 domains do not function
to regulate the in vivo kinase activity of the Abl kinase in cis
but require other cellular factors to exert the differential
modulatory activities seen in cells.
DISCUSSION
In this study, we have constructed a series of mutants of the
Abl kinase designed to probe the function of the SH2 and SH3
ow
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domains. We find that the SH3 domain suppresses the intrinsic
transforming activity of the c-Abl protein in cells but that this
suppression is extremely position dependent and is not appar-
ent in vitro with use of purified proteins. The SH2 domain, on
the other hand, is absolutely required for transforming activity
of Abl mutants; furthermore, the SH2 domain appears to
indirectly determine the spectrum of proteins phosphorylated
in cells. Below, we outline models that are consistent with
these data.
These studies start from the observation that the wild-type
c-Abl protein is poorly transforming, even at relatively high
levels of overexpression, while mutated forms such as v-Abl
and Bcr-Abl have a greatly increased ability to induce the
uncontrolled growth characteristic of transformation and have
elevated in vivo tyrosine kinase activity (10, 15, 32). This
finding suggests that the c-Abl product is tightly regulated in
cells and that mutated forms can escape this regulation. By
analyzing the transforming activity of c-Abl mutants, two issues
are simultaneously addressed: first, the nature of the machin-
ery that normally suppresses c-Abl kinase activity, and second,
the functions required to allow derepressed Abl variants to
transform. While the first issue is clearly relevant to the normal
function of c-Abl, the second issue may not be. We assume,
however, that in some (presently unknown) context, c-Abl
kinase activity might be activated, and that this presumably
transient activated state is mimicked by constitutively activated
transforming variants. Furthermore, understanding the factors
required for Abl transformation has obvious clinical relevance
in diseases such as chronic myelogenous leukemia, in which
activated Abl is strongly implicated.
The transformation assay used in this study is morphological
alteration of monolayer 3T3 cells. While there are many
parameters of cell transformation, we chose morphological
change because it is rapidly and easily scored. One caveat of
this type of analysis should be mentioned, however. It has been
reported that both c-Abl and its transforming variants have a
toxic or cytostatic effect when overexpressed (15, 42). This
observation implies that the scores we report for G418 titers
and focus titers might not reflect the behavior of the majority
of infected cells, since all cells that die or never grow up to a
discernible focus or colony are not scored. Indeed, G418
resistance titers for Abl-containing viruses were generally
lower than titers for the empty virus (GDN), and SH2 domain-
containing variants tended to give lower titers than those
lacking a functional SH2 domain (see Table 1 for a represen-
tative experiment). Given the inherent difficulties in studying
toxicity, however, we leave a more careful analysis of the roles
of SH2 and SH3 domains in this phenomenon for future
studies.
Role of the SH3 domain. It has been known for several years
that deletion of the c-Abl SH3 domain is sufficient to activate
its transforming potential (10, 15). Because SH3 domain
mutations can also activate c-Src (17, 39), it is likely that SH3
domains act to inhibit an intrinsic transforming activity in many
tyrosine kinases that contain them. Our data show that the
ability of the SH3 domain to repress Abl activity is extremely
position sensitive. Moving the SH3 domain relative to other
parts of the protein (the N terminus, SH2 domain, and catalytic
domain) activates the transforming ability of c-Abl at least
20-fold. Many of the positional changes are quite subtle, yet
they result in almost complete derepression of Abl. These
results provide important clues to the possible mechanisms
whereby the SH3 domain might repress catalytic activity in
vivo.' Consistent with our results, another group has found that
substituting heterologous SH2 domains (from GAP or Arg) for
that of c-Abl activates c-Abl transforming activity (31), perhaps
by subtly altering the relationship of the SH3 domain to the
kinase and SH2 domains.
The results from the series of mutants shown in Fig. 2A
make it likely that the physical relationship between the SH3
domain and more than one other part of the protein is
important for repression. If the SH3 domain functioned by
interacting directly or indirectly with a single part of the
protein, one would expect that only mutations affecting the
relationship between the SH3 domain and that part of the
protein would activate. This prediction is not borne out by our
data. Our results also strongly suggest that the SH3 domain
does not function by a simple trans mechanism, for example by
binding to a structural protein and thereby tethering c-Abl in a
subcellular compartment incompatible with transformation. If
this were the case, it is unlikely that subtle changes in the
position of the SH3 domain would affect its activity.
Another possible mechanism for SH3 domain function
would be for it to act in cis to inhibit kinase activity, for
example by binding to some other part of the protein to hold
the protein in a catalytically inactive conformation (reviewed in
reference 56). The SH3 domain of c-Src is proposed to
collaborate with the SH2 domain to inhibit activity by such a
mechanism (51). The Abl SH3 domain is known to bind to
proline-rich sequences, and a 9- or 10-aa high-affinity binding
site has been identified (4, 41). While the C-terminal half of
c-Abl is relatively proline rich, it does not bind with high
affinity to the Abl SH3 domain (40a). Furthermore, if the SH3
domain functioned in cis by binding to Abl itself, the in vitro
kinase activity of c-Abl protein would be expected to be lower
than that of variants lacking the SH3 domain. This is not the
case: using several substrates, we found no difference in the
kinase activity of purified Abl proteins, whether or not the SH3
domain was present.
How, therefore, does the SH3 domain repress the in vivo
activity of c-Abl? Any viable model must explain the position
dependence of the SH3 domain and its inability to inhibit the
activity of purified proteins. The most likely possibility is that
the SH3 domain binds to a cellular factor that inhibits catalytic
activity. The existence of such a factor has been previously
suggested (37). SH3 domains are known to function as protein
association domains during signaling (27), and several high-
affinity Abl SH3 domain ligands have been isolated (4,41). The
observation that in vitro kinase activities are not SH3 domain
dependent suggests that such an inhibitor does not bind tightly
enough to copurify; consistent with this, we have found that it
is difficult to coimmunoprecipitate Abl and known Abl SH3
domain-binding proteins under standard conditions (1). The
extreme position sensitivity of the effect of the SH3 domain
could be explained if the putative inhibitor had to make
specific three-dimensional contacts with multiple surfaces of
the protein in order to inhibit the kinase. For example, it might
be necessary for the inhibitor to precisely interact with the
catalytic active site, and moving the SH3 would make this
interaction sterically unfavorable or even make the SH3 do-
main inaccessible for binding. Previous work has revealed an
Abl catalytic site mutation that can activate transforming
potential in the presence of a normal SH3 domain, consistent
with such a model (16).
While the model outlined above is clearly speculative, it is
consistent with the known behavior of c-Abl and its variants. It
also suggests how the system might be regulated-by modifi-
cation either of the inhibitor or of Abl itself-allowing for an
activated state for c-Abl under some physiological conditions.
It is possible that in such an activated state, the Abl SH3
domain might bind other proteins, such as 3BP-1 (4), which
contains a domain with GAP activity for the Rho/Rac family of
VOL. 14, 1994
2892 MAYER AND BALTIMORE
Ras-like GTP-binding proteins, serving to tie c-Abl into other
signaling pathways. Of course, such potential interactions must
not be required for cell transformation, since SH3 domain-
deleted mutants are fully activated for cell transformation.
Role of the SH2 domain in transformation. Unlike the SH3
domain, the SH2 domain of the Abl kinase plays a positive role
in transformation. If the SH2 domain is deleted, or if it is
mutated at a residue that is critical for binding to phosphoty-
rosine, transforming activity is almost completely lost, even in
the absence of the SH3 domain. Abl proteins that lack a
functional SH2 domain retain wild-type levels of in vitro kinase
activity, assayed with purified proteins made either in insect
cells (Fig. 8) or in immunoprecipitates from infected 293 or
3T3 cells (not shown), suggesting that the SH2 domain does
not function by modulating the kinase domain directly.
These results raise the question of why a tyrosine kinase
would require an SH2 domain, whose function is to tightly bind
to tyrosine-phosphorylated proteins, in order to transform.
Several possibilities will be considered. First, since the non-
transforming c-Abl protein is localized largely in the nucleus
(54), it is possible that the SH2 domain functions (when the
kinase domain is activated, for example by SH3 deletion) to
tether Abl via SH2-phosphotyrosine interactions in the cyto-
plasm, where it must be in order to transform. However, SH3
domain-deleted Abl mutants bearing the R171K mutation that
abolishes SH2 domain function are localized in the cytoplasm
(53a), suggesting that a functional SH2 domain is not necessary
for cytoplasmic localization.
A second possibility is that the SH2 domain functions to
tether substrate proteins to the plasma membrane. In signal
transduction by receptor tyrosine kinases, a critical step of
signaling is the binding of normally cytoplasmic signaling
proteins, such as phospholipase C-y, GAP, PI 3-kinase, and
GRB-2, to the membrane by interaction of their SH2 domains
with phosphotyrosine residues on the activated receptor (re-
viewed in references 33, 35, and 46). Since transforming Abl
variants are myristoylated and at least partially localized on the
plasma membrane (15, 54), the same effect would be achieved
if the Abl kinase phosphorylated such proteins on tyrosine and
then tightly bound them via its SH2 domain. We have tested
this hypothesis by expressing two Abl variants in one cell, the
first containing the R171K mutant SH2 domain and lacking the
SH3 domain, and the second containing a functional SH2
domain but bearing an ATP binding site mutation (K290M)
that inactivates catalytic activity (1Sa). Each of these mutants is
nontransforming when expressed in cells. If binding phosphor-
ylated substrate protein to the membrane were critical, the two
mutants would be expected to complement each other in trans
to induce transformation. We found, however, that expression
of the K290M mutant did not increase the transforming
potential of the R171K mutant (not shown), arguing against
such a model.
An important clue to SH2 domain function was obtained
from the SH2 domain swap experiments. We showed that
heterologous SH2 domains could complement the lack of the
Abl SH2 domain and, more importantly, that cells infected
with mutants bearing heterologous SH2 domains displayed
different patterns of tyrosine-phosphorylated proteins. In fact,
the pattern of phosphoproteins correlated roughly with the
known specificities of the different SH2 domains; i.e., the
phosphorylation of proteins with high affinity for a particular
SH2 domain was enhanced in cells infected with the Abl
mutants bearing that SH2 domain. This was true even if the
catalytic domain was swapped for that of Src, suggesting that
much of the substrate specificity of the nonreceptor tyrosine
kinases might be conferred by the SH2 domain and not the
catalytic domain.
How does the SH2 domain affect substrate specificity? We
propose that what is actually being modulated is not substrate
specificity per se, but the prolonged phosphorylation of pro-
teins that bind to the SH2 domain. Unlike the case for
serine-threonine kinases, there is little in vitro evidence for
substrate specificity for the tyrosine kinases, and it is possible
that they can phosphorylate virtually any phosphotyrosine
residue that is accessible. At the same time, cellular tyrosine
phosphatase activities are very high, so most proteins are
rapidly dephosphorylated in vivo. If the site that is phosphor-
ylated had high affinity for the SH2 domain, however, it could
tightly bind to it; once bound, it would probably be protected
from phosphatases, since several studies have shown that
binding to SH2 domains can protect phosphotyrosine residues
from dephosphorylation in vitro (3, 44). Furthermore, if the
protein is tethered to the kinase via the SH2 domain, the local
concentration of the catalytic domain would be extremely high
and it is likely that the protein would be repeatedly phosphor-
ylated on multiple sites. Both of these mechanisms (protection
from dephosphorylation and repeated phosphorylation) are
likely to play a role, since addition of vanadate, a tyrosine
phosphatase inhibitor, to the culture media of cells infected
with an SH2 domain-deleted mutant increased tyrosine phos-
phorylation on cell proteins, but not to the level seen if the
SH2 domain was present (not shown).
The model outlined above is consistent with our observation
that the SH2 domain is largely position independent when N
terminal to the catalytic domain, because it is unlikely that
precise positioning would be required to bind to proteins
phosphorylated by the catalytic domain, given its high local
concentration. Furthermore, such a model would predict that
SH2 domains would function independently and additively,
consistent with our data from mutants containing both the Abl
and GAP SH2 domains. It is possible that the SH2 domains of
other families of nonreceptor tyrosine kinases perform a
similar role, since SH2 domain mutations in v-Fps and v-Src
can drastically affect transforming activity and substrate phos-
phorylation (18, 43,45, 55). However, as discussed below, there
are also important differences, at least in the case of Src, in
which the SH2 domain also has an inhibitory role.
The model described above implies that the stoichiometry of
tyrosine-phosphorylated substrates to Abl protein itself should
be roughly equimolar, which is consistent with the levels of
proteins seen in antiphosphotyrosine immunoblots. Therefore,
as is the case with the receptor class of tyrosine kinases, it
appears that the Abl nonreceptor kinase signals via stoichio-
metric complexes of proteins without signal amplification. This
picture is very different from the traditional paradigm, taken
from serine-threonine kinases, that kinases amplify signals by
phosphorylating many substrate proteins when activated.
A further implication of the SH2 domain swap experiments
is that many sets of tyrosine-phosphorylated proteins can
induce transformation. The specificities of the SH2 domains
used in these experiments, and thus the spectrum of proteins
that would be phosphorylated in infected cells, are quite
different, yet all of the constructs have considerable transform-
ing activity. It is possible that there are common substrates that
are relatively SH2 domain independent; in fact, all of the
transforming mutants examined increase the phosphorylation
of a protein of approximately 85 kDa (Fig. 4A and SA), which
does not efficiently coimmunoprecipitate with Abl and thus is
probably not bound via the SH2 domain. It is likely, however,
that there is no one critical substrate for transformation and
that many combinations of tyrosine-phosphorylated proteins
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can lead to growth. An analogy could be made to the growth
factor receptors, which contain the binding sites for many SH2
domain-containing proteins; binding of several different pro-
teins individually or in combination can be sufficient to signal
DNA synthesis (53).
The models proposed above for SH2 and SH3 domain
function in Abl are different in several respects from the
functions proposed for these domains in the closely related Src
family of nonreceptor tyrosine kinases (see reference 6 for a
review). In these proteins, the SH2 domain has a largely
inhibitory role on the activity of c-Src, since it interacts with a
regulatory phosphotyrosine (Y-527 in Src) that holds the c-Src
protein in an inactive conformation. The c-Abl protein has no
Y-527 equivalent and no detectable tyrosine phosphorylation
in vivo (38), so such an inhibitory role for the SH2 domain is
implausible. In Src, the positive role for the SH2 domain in
transformation is apparently less important; although SH2
domain mutations can alter and weaken the transformed
phenotype, mutants in which the SH2 domain has been
completely deleted have been reported to be highly transform-
ing (47). The SH3 domain in Src, like that in Abl, is thought to
have an inhibitory role, but unlike the case of Abl, Src SH3
domain mutants have elevated in vitro kinase activity (17).
When c-Src is expressed in Schizosaccharomyces pombe, the
SH3 domain cooperates with the SH2 domain to mediate
binding to the regulatory C-terminal phosphotyrosine (51).
These results indicate that in Src, the SH3 domain functions in
cis, which our data suggest is not the case for Abl. These
differences highlight how diversity of activity and regulation
can evolve from very similar combinations of simple modular
units.
ACKNOWLEDGMENTS
We thank R. Ren for critically reading the manuscript and M. Scott,
W. Sha, T. Fujita, and other members of the laboratory for many
helpful suggestions. We are also grateful to T. Miller for advice about
quantitative kinase assays, P. Jackson for the K290M mutant, and S.
Nagata for the human elongation factor la expression vector.
This work was supported by PHS grants CA 08875 to B.J.M. and CA
51462 to D.B.
REFERENCES
1. Alexandropoulos, K., R. Ren, W. Pear, P. Cicchetti, and D.
Baltimore. Unpublished data.
la.Anderson, D., C. A. Koch, L. Grey, C. Ellis, M. F. Moran, and T.
Pawson. 1990. Binding of SH2 domains of phospholipase Cyl,
GAP, and src to activated growth factor receptors. Science 250:
979-982.
2. Ben-Neriah, Y., A. Bernards, M. Paskind, G. Q. Daley, and D.
Baltimore. 1986. Alternative 5' exons in c-abl mRNA. Cell 44:577-
586.
3. Birge, R. B., J. E. Fajardo, B. J. Mayer, and H. Hanafusa. 1992.
Tyrosine phosphorylated epidermal growth factor receptor and
cellular p130 provide high affinity binding substrates to analyze
crk-phosphotyrosine-dependent interactions in vitro. J. Biol.
Chem. 267:10588-10595.
4. Cicchetti, P., B. J. Mayer, G. Thiel, and D. Baltimore. 1992.
Identification of a protein that binds to the SH3 region of Abl and
is similar to Bcr and GAP-rho. Science 257:803-806.
5. Cooper, J. A. 1990. The src family of protein-tyrosine kinases, p.
85-113. In B. Kemp and P. F. Alewood (ed.), Peptides and protein
phosphorylation. CRC Press, Boca Raton, Fla.
6. Cooper, J. A., and B. Howell. 1993. The when and how of Src
regulation. Cell 73:1051-1054.
7. Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction
of chronic myelogenous leukemia in mice by the P210 bcr/abl gene
of the Philadelphia chromosome. Science 247:824-830).
8. Escobedo, J. A., S. Navankasattusas, W. M. Kavanaugh, D. Milfay,
V. A. Fried, and L. T. Williams. 1991. cDNA cloning of a novel 85
kd protein that has SH2 domains and regulates binding of
P13-kinase to the PDGF [3-receptor. Cell 65:75-82.
9. Foulkes, J. G., M. Chow, C. Gorka, A. R. Frackelton, Jr., and D.
Baltimore. 1985. Purification and characterization of a protein-
tyrosine kinase encoded by the Abelson murine leukemia virus. J.
Biol. Chem. 260:8070-8077.
10. Franz, W. M., P. Berger, and J. Y. J. Wang. 1989. Deletion of an
N-terminal regulatory domain of the c-abl tyrosine kinase activates
its oncogenic potential. EMBO J. 8:137-147.
11. Glenney, J. R., L. Zokas, and M. P. Kamps. 1988. Monoclonal
antibodies to phosphotyrosine. J. Immunol. Methods 109:277-285.
12. Goff, S. P., E. Gilboa, 0. N. Witte, and D. Baltimore. 1980.
Structure of the Abelson murine leukemia virus genome and the
homologous cellular gene: studies with cloned viral DNA. Cell
22:777-785.
13. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein
kinase family: conserved features and deduced phylogeny of the
catalytic domains. Science 241:42-52.
14. Hunter, T. 1991. Cooperation between oncogenes. Cell 64:249-
270.
15. Jackson, P., and D. Baltimore. 1989. N-terminal mutations acti-
vate the leukemogenic potential of the myristoylated form of c-abl.
EMBO J. 8:449-456.
15a.Jackson, P., and D. Baltimore. Unpublished data.
16. Jackson, P. K., M. Paskind, and D. Baltimore. 1993. Mutation of
a phenylalanine conserved in SH3-containing tyrosine kinases
activates the transforming ability of c-Abl. Oncogene 8:1943-1956.
17. Kato, J.-Y., T. Takeya, C. Grandori, H. Iba, J. B. Levy, and H.
Hanafusa. 1986. Amino acid substitutions sufficient to convert the
nontransforming p60c-r' protein to a transforming protein. Mol.
Cell. Biol. 6:4155-4160.
18. Koch, C. A., M. F. Moran, I. Sadowski, and T. Pawson. 1989. The
common src homology region 2 domain of cytoplasmic signaling
proteins is a positive effector of v-fps tyrosine kinase function. Mol.
Cell. Biol. 9:4131-4140.
19. Konopka, J. B., R. L. Davis, S. M. Watanabe, A. S. Ponticelli, L.
Schiff-Maker, N. Rosenberg, and 0. N. Witte. 1984. Only site-
directed antibodies reactive with the highly conserved src-homol-
ogous region of the v-abl protein neutralize kinase activity. J.
Virol. 51:223-232.
20. Margolis, B., N. Li, A. Koch, M. Mohammadi, D. R. Hurwitz, A.
Zilberstein, A. Ullrich, T. Pawson, and J. Schlessinger. 1990. The
tyrosine-phosphorylated carboxyterminus of the EGF receptor is a
binding site for GAP and PLC-y. EMBO J. 9:4375-4380.
21. Martinez, R., B. Mathey-Prevot, A. Bernards, and D. Baltimore.
1987. Neuronal pp60c`rc contains a six-amino acid insertion rela-
tive to its non-neuronal counterpart. Science 237:411-415.
22. Matsuda, M., B. J. Mayer, Y. Fukui, and H. Hanafusa. 1990.
Binding of transforming protein, p479z'-crk to a broad range of
phosphotyrosine-containing proteins. Science 248:1537-1539.
23. Matsuda, M., B. J. Mayer, and H. Hanafusa. 1991. Identification
of domains of the v-crk oncogene product sufficient for association
with phosphotyrosine-containing proteins. Mol. Cell. Biol. 11:
1607-1613.
24. Mayer, B. J., and D. Baltimore. 1993. Signalling through SH2 and
SH3 domains. Trends Cell Biol. 3:8-13.
24a.Mayer, B. J., and D. Baltimore. Unpublished data.
25. Mayer, B. J., P. K. Jackson, and D. Baltimore. 1991. The noncata-
lytic src homology region 2 segment of abl tyrosine kinase binds to
tyrosine-phosphorylated cellular proteins with high affinity. Proc.
Natl. Acad. Sci. USA 88:627-631.
26. Mayer, B. J., P. K. Jackson, R. A. Van Etten, and D. Baltimore.
1992. Point mutations in the abl SH2 domain coordinately impair
phosphotyrosine binding in vitro and transforming activity in vivo.
Mol. Cell. Biol. 12:609-618.
27. McCormick, F. 1993. How receptors turn ras on. Nature (London)
363:15-16.
28. Mes-Masson, A.-M., J. McLaughlin, G. Q. Daley, M. Paskind, and
0. N. Witte. 1986. Overlapping cDNA clones define the complete
coding region for the P21 oc-ah gene product associated with
chronic myelogenous leukemia cells containing the Philadelphia
chromosome. Proc. Natl. Acad. Sci. USA 83:9768-9772.
29. Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful
VOL. 14, 1994
2894 MAYER AND BALTIMORE
mammalian expression vector. Nucleic Acids Res. 18:5322.
30. Moran, M. F., C. A. Koch, D. Anderson, C. Ellis, L. England, G. S.
Martin, and T. Pawson. 1990. Src homology region 2 domains
direct protein-protein interactions in signal transduction. Proc.
Natl. Acad. Sci. USA 87:8622-8626.
31. Muller, A. J., A. M. Pendergast, K. Parmar, M. H. Havlik, N.
Rosenberg, and 0. N. Witte. 1993. En bloc substitution of the Src
homology region 2 domain activates the transforming potential of
the c-Abl protein-tyrosine kinase. Proc. Natl. Acad. Sci. USA
90:3457-3461.
32. Muller, A. J., J. C. Young, A. M. Pendergast, M. Pondel, N.
Landau, D. R. Littman, and 0. N. Witte. 1991. BCR first exon
sequences specifically activate the BCR/ABL tyrosine kinase on-
cogene of Philadelphia chromosome-positive human leukemias.
Mol. Cell. Biol. 11:1785-1792.
33. Panayotou, G., and M. D. Waterfield. 1993. The assembly of
signalling complexes by receptor tyrosine kinases. Bioessays 15:
171-177.
34. Pawson, T., and G. Gish. 1992. SH2 and SH3 domains: from
structure to function. Cell 71:359-362.
35. Pazin, M. J., and L. T. Williams. 1992. Triggering signalling
cascades by receptor tyrosine kinases. Trends Biochem. Sci. 17:
374-378.
36. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993.
Production of high-titer helper-free retroviruses by transient trans-
fection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
37. Pendergast, A. M., A. J. Muller, M. H. Havlik, R. Clark, F.
McCormick, and 0. N. Witte. 1991. Evidence for regulation of the
human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl.
Acad. Sci. USA 88:5927-5931.
38. Ponticelli, A. S., C. A. Whitlock, N. Rosenberg, and 0. N. Witte.
1982. In vivo tyrosine phosphorylations of the abelson virus
transforming protein are absent in its normal cellular homolog.
Cell 29:953-960.
39. Potts, W. M., A. B. Reynolds, T. J. Lansing, and J. T. Parsons.
1988. Activation of pp6ocsrc transforming potential by mutations
altering the structure of an amino terminal domain containing
residues 90-95. Oncogene Res. 3:343-355.
40. Reichman, C. T., B. J. Mayer, S. Keshav, and H. Hanafusa. 1992.
The product of the cellular crk gene consists primarily of SH2 and
SH3 regions. Cell Growth Differ. 3:451-460.
40a.Ren, R., K. Alexandropoulos, and D. Baltimore. Unpublished data.
41. Ren, R., B. J. Mayer, P. Cicchetti, and D. Baltimore. 1993.
Identification of a 10-amino acid proline-rich SH3 binding site.
Science 259:1157-1161.
42. Renshaw, M. W., E. T. Kipreos, M. R. Albrecht, and J. Y. J. Wang.
1992. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate
growth, depending on the cell context. EMBO J. 11:3941-3951.
43. Reynolds, A. B., S. B. Kanner, H.-C. R. Wang, and J. T. Parsons.
1989. Stable association of activated pp60Yrc with two tyrosine-
phosphorylated cellular proteins. Mol. Cell. Biol. 9:3951-3958.
44. Rotin, D., B. Margolis, M. Mohammadi, R. J. Daly, G. Daum, N.
Li, E. H. Fischer, W. H. Burgess, A. Ullrich, and J. Schlessinger.
1992. SH2 domains prevent tyrosine dephosphorylation of the
EGF receptor: identification of Tyr992 as the high-affinity binding
site for SH2 domains of phospholipase Cy. EMBO J. 11:559-567.
45. Sadowski, I., J. C. Stone, and T. Pawson. 1986. A noncatalytic
domain conserved among cytoplasmic protein-tyrosine kinases
modifies the kinase function and transforming activity of Fujinami
sarcoma virus PO30faz-fPs. Mol. Cell. Biol. 6:4396-4408.
46. Schlessinger, J., and A. Ullrich. 1992. Growth factor signaling by
receptor tyrosine kinases. Neuron 9:383-391.
47. Seidel-Dugan, C., B. E. Meyer, S. M. Thomas, and J. S. Brugge.
1992. Effects of SH2 and SH3 deletions on the functional activities
of wild-type and transforming variants of c-Src. Mol. Cell. Biol.
12:1835-1845.
48. Shtivelman, E., B. Lifshitz, R. P. Gale, and E. Canaani. 1985.
Fused transcript of abl and bcr genes in chronic myelogenous
leukaemia. Nature (London) 315:550-554.
49. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of
polypeptides expressed in Escherichia coli as fusions with glutathi-
one S-transferase. Gene 67:31-40.
50. Songyang, Z., S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson,
W. G. Haser, F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider,
B. G. Neel, R. B. Birge, J. E. Fajardo, M. M. Chou, H. Hanafusa,
B. Shaffhausen, and L C. Cantley. 1993. SH2 domains recognize
specific phosphopeptide sequences. Cell 72:767-778.
51. Superti-Furga, G., S. Fumagalli, M. Koegl, S. A. Courtneidge, and
G. Draetta. 1993. Csk inhibition of c-Src activity requires both the
SH2 and SH3 domains of Src. EMBO J. 12:2625-2634.
52. Trahey, M., G. Wong, R. Halenbeck, B. Rubinfeld, G. A. Martin,
M. Ladner, C. M. Long, W. J. Crosier, K. Watt, K. Koths, and F.
McCormick. 1988. Molecular cloning of two types of GAP cDNA
from human placenta. Science 242:1697-1700.
53. Valius, M., and A. Kazlauskas. 1993. Phospholipase C-yl and
phosphatidylinositol 3 kinase are the downstream mediators of the
PDGF receptor's mitogenic signal. Cell 73:321-334.
53a.Van Etten, R. Personal communication.
54. Van Etten, R. A., P. Jackson, and D. Baltimore. 1989. The mouse
type IV c-abl gene product is a nuclear protein, and activation of
transforming ability is associated with cytoplasmic localization.
Cell 58:669-678.
55. Wang, H.-C., and J. T. Parsons. 1989. Deletions and insertions
within an amino-terminal domain of pp60vsrc inactivate transfor-
mation and modulate membrane stability. J. Virol. 63:291-302.
56. Wang, J. Y. J. 1993. Abl tyrosine kinase in signal transduction and
cell-cycle regulation. Curr. Opin. Genet. Dev. 3:35-43.
MOL. CELL. BIOL.
